GSK notches clinical win with anti-BCMA ADC amid cancer pipeline push

GlaxoSmithKline's return to cancer took another large step forward as one of its most prominent oncology candidates succeeded in a pivotal Phase II trial to treat multiple myeloma.

On Friday, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said anti-BCMA antibody-drug conjugate belantamab mafodotin (GSK2857916) met the primary endpoint of overall response rate (ORR) in the pivotal Phase II DREAMM-2 trial in 196 patients with relapsed/refractory fourth-line multiple myeloma...